The Motley Fool··Adria CiminoViking Therapeutics Advances Obesity Treatment Pipeline Ahead of 2026 Trial Milestones
Viking Therapeutics advances obesity drug VK2735 through phase 3 trials, expecting 2026 trial data. Dual GIP/GLP-1 agonist targets $100B+ market opportunity.
LLYNVOVKTXbiotechclinical trials